Optimi Health Secures Ibogaine Supplies, Launches 50mg and 100mg Capsule Development
OPTH•Optimi Health secured ibogaine in hydrochloride and freebase forms and will begin finished drug product development this summer at its GMP facility in British Columbia with 50mg and 100mg dosages. US executive order prioritizes ibogaine for expedited FDA review and matches federal funding to state psychedelic research.
1. Dual-Source Ibogaine Supply
Optimi Health has obtained naturally derived ibogaine in both hydrochloride and freebase forms from two independent suppliers, ensuring raw material availability for its development program.
2. Upcoming Finished Drug Development
Development of encapsulated ibogaine products is scheduled to begin this summer at Optimi’s GMP facility in British Columbia, with planned dosage strengths of 50mg and 100mg alongside standard operating procedures for encapsulation, labeling, and analytical method validation.
3. Regulatory Tailwinds and Strategic Positioning
A recent US executive order designates ibogaine for expedited FDA review and aligns federal funding with state psychedelic research, while Canada’s regulatory framework allows compliant manufacture under the Prescription Drug List, positioning Optimi as a key supplier for clinical and therapeutic programs.
